CoChat
Sign Up
Cited by 56Genetics and Neurodevelopmental DisordersNeurogenesis and neuroplasticity mechanismsDevelopmental Biology and Gene Regulation

Progress on the Roles of MEF2C in Neuropsychiatric Diseases

Open access
Zhang, Zhikun, Zhao, Yongxiang·2022·Molecular Brain
DOI 10.1186/s13041-021-00892-6PMC PMC8740500
Open this paper in CoChat — free accountOpen PDF

Abstract

Myocyte Enhancer Factor 2 C (MEF2C), one of the transcription factors of the MADS-BOX family, is involved in embryonic brain development, neuronal formation and differentiation, as well as in the growth and pruning of axons and dendrites. MEF2C is also involved in the development of various neuropsychiatric disorders, such as autism spectrum disorders (ASD), epilepsy, schizophrenia and Alzheimer's disease (AD). Here, we review the relationship between MEF2C and neuropsychiatric disorders, and provide further insights into the mechanism of these diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13041-021-00892-6

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MEF2C exerts anti-inflammatory effects within the brain by suppressing the expression of proinflammatory cytokines and protecting neurons from inflammatory damage.

    “MEF2C exerts anti‐inflammatory effects within the brain by suppressing the expression of proinflammatory cytokines and protecting neurons from inflammatory damage.”

    From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [44]

    The Alzheimer’s disease section reports higher proinflammatory cytokine levels in MEF2C-knockout mice after immune activation, supporting an anti-inflammatory role for MEF2C in microglia. It separately describes MEF2C’s role in anti-apoptotic neuroprotection, but does not say that MEF2C protects neurons specifically from inflammatory damage. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • MEF2C is a transcription factor with crucial roles in immune regulation, synaptic plasticity, and neuronal survival.

    “MEF2C is a transcription factor with crucial roles in immune regulation, synaptic plasticity, and neuronal survival [43, 44].”

    From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [44]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 76

  1. [1]Adachi M Lin PY Pranav H Monteggia LM Postnatal loss of Mef2c results in dissociation of effects on synapse number and learning and memory Biol Psychiatry 2016 80 2 140 148 10.1016/j.biopsych.2015.09.018 26642739 PMC4826326 · DOI
  2. [2]Akhtar MW Kim MS Adachi M Morris MJ Qi X Richardson JA In vivo analysis of MEF2 transcription factors in synapse regulation and neuronal survival PLoS ONE 2012 7 4 e34863 10.1371/journal.pone.0034863 22496871 PMC3322166 · DOI
  3. [3]Angelelli C Magli A Ferrari D Ganassi M Matafora V Parise F Differentiation-dependent lysine 4 acetylation enhances MEF2C binding to DNA in skeletal muscle cells Nucleic Acids Res 2008 36 3 915 928 10.1093/nar/gkm1114 18086704 PMC2241889 · DOI
  4. [5]Bai XL Zhang Q Ye LY Liang F Sun X Chen Y Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/beta-catenin signaling Oncogene 2015 34 31 4089 4097 10.1038/onc.2014.337 25328135 · DOI
  5. [6]Barbosa AC Kim MS Ertunc M Adachi M Nelson ED McAnally J MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function Proc Natl Acad Sci U S A 2008 105 27 9391 9396 10.1073/pnas.0802679105 18599438 PMC2453723 · DOI · Paper page
  6. [7]Bienvenu T Diebold B Chelly J Isidor B Refining the phenotype associated with MEF2C point mutations Neurogenetics 2013 14 1 71 75 10.1007/s10048-012-0344-7 23001426 · DOI
  7. [8]Boden KA Barber IS Clement N Patel T Guetta-Baranes T Brookes KJ Methylation profiling RIN3 and MEF2C identifies epigenetic marks associated with sporadic early onset Alzheimer’s disease J Alzheimers Dis Rep 2017 1 1 97 108 10.3233/ADR-170015 30480232 PMC6159661 · DOI
  8. [9]Borlot F Whitney R Cohn RD Weiss SK MEF2C-related epilepsy: delineating the phenotypic spectrum from a novel mutation and literature review Seizure 2019 67 86 90 10.1016/j.seizure.2019.03.015 30922778 · DOI
  9. [10]Boutry-Kryza N Labalme A Ville D de Bellescize J Touraine R Prieur F Molecular characterization of a cohort of 73 patients with infantile spasms syndrome Eur J Med Genet 2015 58 2 51 58 10.1016/j.ejmg.2014.11.007 25497044 · DOI
  10. [11]Brown FC Still E Koche RP Yim CY Takao S Cifani P MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia Cancer Discov 2018 8 4 478 497 10.1158/2159-8290.CD-17-1271 29431698 PMC5882571 · DOI
  11. [12]Burton TR Dibrov A Kashourd T Amara FM Anti-apoptotic wild-type Alzheimer amyloid precursor protein signaling involves the p38 mitogen-activated protein kinase/MEF2 pathway Mol Brain Res 2002 108 1–2 18 10.1016/S0169-328X(02)00519-3 12480183 · DOI
  12. [13]Camargo LM Zhang XD Loerch P Caceres RM Marine SD Uva P Pathway-based analysis of genome-wide siRNA screens reveals the regulatory landscape of APP processing PLoS ONE 2015 10 2 e0115369 10.1371/journal.pone.0115369 25723573 PMC4344212 · DOI
  13. [14]Cardoso C Boys A Parrini E Mignon-Ravix C McMahon JM Khantane S Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion Neurology 2009 72 9 784 792 10.1212/01.wnl.0000336339.08878.2d 19073947 · DOI
  14. [17]Chen X Gao B Ponnusamy M Lin Z Liu J MEF2 signaling and human diseases Oncotarget 2017 8 67 112152 112165 10.18632/oncotarget.22899 29340119 PMC5762387 · DOI
  15. [18]Chen YC Kuo HY Bornschein U Takahashi H Chen SY Lu KM Foxp2 controls synaptic wiring of corticostriatal circuits and vocal communication by opposing Mef2c Nat Neurosci 2016 19 11 1513 1522 10.1038/nn.4380 27595386 PMC5083203 · DOI
  16. [19]Chidambaram H Das R Chinnathambi S Interaction of Tau with the chemokine receptor, CX3CR1 and its effect on microglial activation, migration and proliferation Cell Biosci 2020 10 109 10.1186/s13578-020-00474-4 32944223 PMC7493323 · DOI
  17. [21]Di Giorgio E Hancock WW Brancolini C MEF2 and the tumorigenic process, hic sunt leones Biochim Biophys Acta Rev Cancer 2018 1870 2 261 273 10.1016/j.bbcan.2018.05.007 29879430 · DOI
  18. [22]Engels H Wohlleber E Zink A Hoyer J Ludwig KU Brockschmidt FF A novel microdeletion syndrome involving 5q14.3-q15: clinical and molecular cytogenetic characterization of three patients Eur J Hum Genet 2009 17 12 1592 1599 10.1038/ejhg.2009.90 19471318 PMC2987012 · DOI
  19. [23]Flavell SW Kim TK Gray JM Harmin DA Hemberg M Hong EJ Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection Neuron 2008 60 6 1022 1038 10.1016/j.neuron.2008.11.029 19109909 PMC2630178 · DOI · Paper page
  20. [24]Galego S Kauppila LA Malho R Pimentel J Brito MA Myocyte enhancer factor 2C as a new player in human breast cancer brain metastases Cells 2021 10.3390/cells10020378 33673112 PMC7917785 · DOI
  21. [25]Gu X Fu C Lin L Liu S Su X Li A miR-124 and miR-9 mediated downregulation of HDAC5 promotes neurite development through activating MEF2C-GPM6A pathway J Cell Physiol 2018 233 1 673 687 10.1002/jcp.25927 28332716 · DOI
  22. [26]Harrington AJ Raissi A Rajkovich K Berto S Kumar J Molinaro G MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to neurodevelopmental disorders Elife 2016 10.7554/eLife.20059 27779093 PMC5094851 · DOI · Paper page
  23. [27]Hashimoto K Kano M Synapse elimination in the developing cerebellum Cell Mol Life Sci 2013 70 24 4667 4680 10.1007/s00018-013-1405-2 23811844 PMC3830199 · DOI
  24. [29]Jansen IE Savage JE Watanabe K Bryois J Williams DM Steinberg S Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk Nat Genet 2019 51 3 404 413 10.1038/s41588-018-0311-9 30617256 PMC6836675 · DOI · Paper page
  25. [30]Javidfar B Park R Kassim BS Bicks LK Akbarian S The epigenomics of schizophrenia, in the mouse Am J Med Genet B Neuropsychiatr Genet 2017 174 6 631 640 10.1002/ajmg.b.32566 28699694 PMC5573750 · DOI
  26. [32]Kamath S Chen A Myocyte enhancer factor 2c regulates dendritic complexity and connectivity of cerebellar Purkinje cells Mol Neurobiol 2019 56 6 4102 4119 10.1007/s12035-018-1363-7 30276662 PMC6505522 · DOI
  27. [33]Kim B Choi Y Kim HS Im HI Methyl-CpG binding protein 2 in Alzheimer dementia Int Neurourol J 2019 23 Suppl 2 S72 81 10.5213/inj.1938196.098 31795606 PMC6905210 · DOI
  28. [34]Kunkle BW Grenier-Boley B Sims R Bis JC Damotte V Naj AC Environmental Risk for Alzheimer's Disease, C. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing Nat Genet 2019 51 3 414 430 10.1038/s41588-019-0358-2 30820047 PMC6463297 · DOI · Paper page
  29. [35]Lambert JC Ibrahim-Verbaas CA Harold D Naj AC Sims R Bellenguez C Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease Nat Genet 2013 45 12 1452 1458 10.1038/ng.2802 24162737 PMC3896259 · DOI · Paper page
  30. [36]Le Meur N Holder-Espinasse M Jaillard S Goldenberg A Joriot S Amati-Bonneau P MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations J Med Genet 2010 47 1 22 29 10.1136/jmg.2009.069732 19592390 PMC2848840 · DOI
  31. [37]Li H Radford JC Ragusa MJ Shea KL McKercher SR Zaremba JD Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo Proc Natl Acad Sci U S A 2008 105 27 9397 9402 10.1073/pnas.0802876105 18599437 PMC2453715 · DOI
  32. [38]Li H Zhong X Chau KF Williams EC Chang Q Loss of activity-induced phosphorylation of MeCP2 enhances synaptogenesis, LTP and spatial memory Nat Neurosci 2011 14 8 1001 1008 10.1038/nn.2866 21765426 PMC3273496 · DOI
  33. [39]Li Z McKercher SR Cui J Nie Z Soussou W Roberts AJ Myocyte enhancer factor 2C as a neurogenic and antiapoptotic transcription factor in murine embryonic stem cells J Neurosci 2008 28 26 6557 6568 10.1523/JNEUROSCI.0134-08.2008 18579729 PMC2679693 · DOI
  34. [40]Lim ASP Gaiteri C Yu L Sohail S Swardfager W Tasaki S Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: analysis of multiple cohorts PLoS Med 2018 15 9 e1002647 10.1371/journal.pmed.1002647 30180184 PMC6122787 · DOI
  35. [41]Lin E Tsai SJ Kuo PH Liu YL Yang AC Kao CF Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population Oncotarget 2017 8 15 24077 24087 10.18632/oncotarget.15269 28199971 PMC5421828 · DOI · Paper page
  36. [43]Ma Q Telese F Genome-wide epigenetic analysis of MEF2A and MEF2C transcription factors in mouse cortical neurons Commun Integr Biol 2015 8 6 e1087624 10.1080/19420889.2015.1087624 27066173 PMC4802763 · DOI
  37. [44]Madugula K Mulherkar R Khan ZK Chigbu DI Patel D Harhaj EW Jain P MEF-2 isoforms’ (A-D) roles in development and tumorigenesis Oncotarget 2019 10 28 2755 2787 10.18632/oncotarget.26763 31105874 PMC6505634 · DOI
  38. [45]Martinez-Cerdeno V Dendrite and spine modifications in autism and related neurodevelopmental disorders in patients and animal models Dev Neurobiol 2017 77 4 393 404 10.1002/dneu.22417 27390186 PMC5219951 · DOI · Paper page
  39. [46]McKinsey TA Zhang CL Lu J Olson EN Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation Nature 2000 408 6808 106 111 10.1038/35040593 11081517 PMC4459600 · DOI
  40. [47]Mitchell AC Javidfar B Pothula V Ibi D Shen EY Peter CJ MEF2C transcription factor is associated with the genetic and epigenetic risk architecture of schizophrenia and improves cognition in mice Mol Psychiatry 2018 23 1 123 132 10.1038/mp.2016.254 28115742 PMC5966823 · DOI
  41. [48]Nettiksimmons J Tranah G Evans DS Yokoyama JS Yaffe K Gene-based aggregate SNP associations between candidate AD genes and cognitive decline Age (Dordr) 2016 38 2 41 10.1007/s11357-016-9885-2 27005436 PMC5005889 · DOI
  42. [49]Novara F Beri S Giorda R Ortibus E Nageshappa S Darra F Refining the phenotype associated with MEF2C haploinsufficiency Clin Genet 2010 78 5 471 477 10.1111/j.1399-0004.2010.01413.x 20412115 · DOI
  43. [50]Nurnberger JI Jr Koller DL Jung J Edenberg HJ Foroud T Guella I Psychiatric Genomics Consortium Bipolar, G. Identification of pathways for bipolar disorder: a meta-analysis JAMA Psychiat 2014 71 6 657 664 10.1001/jamapsychiatry.2014.176 PMC4523227 24718920 · DOI · Paper page
  44. [51]Ohi K Shimada T Nitta Y Kihara H Okubo H Uehara T Kawasaki Y Specific gene expression patterns of 108 schizophrenia-associated loci in cortex Schizophr Res 2016 174 1–3 35 38 10.1016/j.schres.2016.03.032 27061659 · DOI
  45. [52]Okamoto S Nakamura T Cieplak P Chan SF Kalashnikova E Liao L S-nitrosylation-mediated redox transcriptional switch modulates neurogenesis and neuronal cell death Cell Rep 2014 8 1 217 228 10.1016/j.celrep.2014.06.005 25001280 PMC4114155 · DOI
  46. [54]Perea JR Bolos M Avila J Microglia in Alzheimer’s disease in the context of tau pathology Biomolecules 2020 10.3390/biom10101439 33066368 PMC7602223 · DOI
  47. [55]Proschel C Hansen JN Ali A Tuttle E Lacagnina M Buscaglia G Epilepsy-causing sequence variations in SIK1 disrupt synaptic activity response gene expression and affect neuronal morphology Eur J Hum Genet 2017 25 2 216 221 10.1038/ejhg.2016.145 27966542 PMC5255945 · DOI
  48. [56]Rajkovich KE Loerwald KW Hale CF Hess CT Gibson JR Huber KM Experience-dependent and differential regulation of local and long-range excitatory neocortical circuits by postsynaptic Mef2c Neuron 2017 93 1 48 56 10.1016/j.neuron.2016.11.022 27989458 PMC5215966 · DOI
  49. [57]Rocha H Sampaio M Rocha R Fernandes S Leao M MEF2C haploinsufficiency syndrome: report of a new MEF2C mutation and review Eur J Med Genet 2016 59 9 478 482 10.1016/j.ejmg.2016.05.017 27255693 · DOI
  50. [58]Ruiz A Heilmann S Becker T Hernandez I Wagner H Thelen M Follow-up of loci from the International Genomics of Alzheimer’s disease project identifies TRIP4 as a novel susceptibility gene Transl Psychiatry 2014 4 e358 10.1038/tp.2014.2 24495969 PMC3944635 · DOI · Paper page
  51. [59]Ryan SD Dolatabadi N Chan SF Zhang X Akhtar MW Parker J Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription Cell 2013 155 6 1351 1364 10.1016/j.cell.2013.11.009 24290359 PMC4028128 · DOI
  52. [60]Sao T Yoshino Y Yamazaki K Ozaki Y Mori Y Ochi S MEF2C mRNA expression and cognitive function in Japanese patients with Alzheimer’s disease Psychiatry Clin Neurosci 2018 72 3 160 167 10.1111/pcn.12618 29112298 · DOI
  53. [61]Sereno M Hasko J Molnar K Medina SJ Reisz Z Malho R Downregulation of circulating miR 802–5p and miR 194–5p and upregulation of brain MEF2C along breast cancer brain metastasization Mol Oncol 2020 14 3 520 538 10.1002/1878-0261.12632 31930767 PMC7053247 · DOI
  54. [62]Shadrin AA Smeland OB Zayats T Schork AJ Frei O Bettella F Novel loci associated with attention-deficit/hyperactivity disorder are revealed by leveraging polygenic overlap with educational attainment J Am Acad Child Adolesc Psychiatry 2018 57 2 86 95 10.1016/j.jaac.2017.11.013 29413154 PMC5806128 · DOI
  55. [63]Shalizi A Gaudilliere B Yuan Z Stegmuller J Shirogane T Ge Q A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation Science 2006 311 5763 1012 1017 10.1126/science.1122513 16484498 · DOI
  56. [64]Shim JS Min K Lee SH Park JE Park SH Kim M Shim SH MEF2C-related 5q14.3 microdeletion syndrome detected by array CGH: a case report Ann Rehabil Med 2015 39 3 482 487 10.5535/arm.2015.39.3.482 26161356 PMC4496521 · DOI
  57. [65]Srivastava S Cohen JS Vernon H Baranano K McClellan R Jamal L Clinical whole exome sequencing in child neurology practice Ann Neurol 2014 76 4 473 483 10.1002/ana.24251 25131622 · DOI
  58. [66]Tang SS Wang HF Zhang W Kong LL Zheng ZJ Tan MS MEF2C rs190982 polymorphism with late-onset Alzheimer’s disease in Han Chinese: a replication study and meta-analyses Oncotarget 2016 7 26 39136 39142 10.18632/oncotarget.9819 27276684 PMC5129919 · DOI · Paper page
  59. [68]Tanteles GA Alexandrou A Evangelidou P Gavatha M Anastasiadou V Sismani C Partial MEF2C deletion in a Cypriot patient with severe intellectual disability and a jugular fossa malformation: review of the literature Am J Med Genet A 2015 167A 3 664 669 10.1002/ajmg.a.36945 25691421 · DOI
  60. [70]Tu S Akhtar MW Escorihuela RM Amador-Arjona A Swarup V Parker J NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism Nat Commun 2017 8 1 1488 10.1038/s41467-017-01563-8 29133852 PMC5684358 · DOI
  61. [71]Vangoor VR Reschke CR Senthilkumar K van de Haar LL de Wit M Giuliani G Antagonizing increased miR-135a levels at the chronic stage of experimental TLE reduces spontaneous recurrent seizures J Neurosci 2019 39 26 5064 5079 10.1523/JNEUROSCI.3014-18.2019 31015341 PMC6595945 · DOI
  62. [72]Vidal S Brandi N Pacheco P Maynou J Fernandez G Xiol C The most recurrent monogenic disorders that overlap with the phenotype of Rett syndrome Eur J Paediatr Neurol 2019 23 4 609 620 10.1016/j.ejpn.2019.04.006 31105003 · DOI
  63. [73]Vrecar I Innes J Jones EA Kingston H Reardon W Kerr B Further clinical delineation of the MEF2C haploinsufficiency syndrome: report on new cases and literature review of severe neurodevelopmental disorders presenting with seizures, absent speech, and involuntary movements J Pediatr Genet 2017 6 3 129 141 10.1055/s-0037-1601335 28794905 PMC5548525 · DOI
  64. [74]Wang J Zhang Q Chen Y Yu S Wu X Bao X Rett and Rett-like syndrome: expanding the genetic spectrum to KIF1A and GRIN1 gene Mol Genet Genomic Med 2019 7 11 e968 10.1002/mgg3.968 31512412 PMC6825848 · DOI
  65. [75]Wang J Zhang Q Chen Y Yu S Wu X Bao X Wen Y Novel MEF2C point mutations in Chinese patients with Rett (-like) syndrome or non-syndromic intellectual disability: insights into genotype-phenotype correlation BMC Med Genet 2018 19 1 191 10.1186/s12881-018-0699-1 30376817 PMC6208086 · DOI
  66. [76]Wu MC Kraft P Epstein MP Taylor DM Chanock SJ Hunter DJ Lin X Powerful SNP-set analysis for case-control genome-wide association studies Am J Hum Genet 2010 86 6 929 942 10.1016/j.ajhg.2010.05.002 20560208 PMC3032061 · DOI
  67. [77]Xue W Chen J Liu X Gong W Zheng J Guo X PVT1 regulates the malignant behaviors of human glioma cells by targeting miR-190a-5p and miR-488–3p Biochim Biophys Acta Mol Basis Dis 2018 1864 5 pt A 1783 1794 10.1016/j.bbadis.2018.02.022 29501773 · DOI
  68. [78]Yang Y Ren M Song C Li D Soomro SH Xiong Y LINC00461, a long non-coding RNA, is important for the proliferation and migration of glioma cells Oncotarget 2017 8 48 84123 84139 10.18632/oncotarget.20340 29137410 PMC5663582 · DOI
  69. [79]Yu D Li S Jiang N Infantile spasm associated with 5q143 microdeletion syndrome: clinical and genetic characterization of a core family Zhonghua Er Ke Za Zhi 2015 53 2 140 142 25876691
  70. [80]Yu Q Zhao MW Yang P LncRNA UCA1 suppresses the inflammation via modulating miR-203-mediated regulation of MEF2C/NF-kappaB signaling pathway in epilepsy Neurochem Res 2020 45 4 783 795 10.1007/s11064-019-02952-9 32056051 · DOI
  71. [81]Zhang ZG Li Y Ng CT Song YQ Inflammation in Alzheimer’s disease and molecular genetics: recent update Arch Immunol Ther Exp (Warsz) 2015 63 5 333 344 10.1007/s00005-015-0351-0 26232392 · DOI
  72. [82]Zhou T Su W Liang D Xu Y Luo Y Tong G Genetic analysis of a case with MEF2C deletion in association with 5q14.3 microdeletion syndrome Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2021 38 8 779 782 10.3760/cma.j.cn511374-20200608-00417 34365624 · DOI
  73. [83]Zhou WZ Zhang J Li Z Lin X Li J Wang S Targeted resequencing of 358 candidate genes for autism spectrum disorder in a Chinese cohort reveals diagnostic potential and genotype-phenotype correlations Hum Mutat 2019 40 6 801 815 10.1002/humu.23724 30763456 PMC6593842 · DOI
  74. [84]Zhu B Carmichael RE Solabre Valois L Wilkinson KA Henley JM The transcription factor MEF2A plays a key role in the differentiation/maturation of rat neural stem cells into neurons Biochem Biophys Res Commun 2018 500 3 645 649 10.1016/j.bbrc.2018.04.125 29678571 PMC5956278 · DOI
  75. [85]Zhu B Gulick T Phosphorylation and alternative pre-mRNA splicing converge to regulate myocyte enhancer factor 2C activity Mol Cell Biol 2004 24 18 8264 8275 10.1128/MCB.24.18.8264-8275.2004 15340086 PMC515034 · DOI
  76. [86]Zweier M Gregor A Zweier C Engels H Sticht H Wohlleber E Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression Hum Mutat 2010 31 6 722 733 10.1002/humu.21253 20513142 · DOI

Cited by

Sorted by citations

Authors
Zhang, Z., & Zhao, Y.
Affiliations
Guangxi Medical University (CN)
Corresponding author
Zhao, Yongxiang
ORCID
Venue
Molecular Brain
Publisher
Springer Science and Business Media LLC
Published
2022-01-06
Volume
15
Issue
1
Pages
8-8
ISSN
1756-6606 (ISSN-L)
DOI
10.1186/s13041-021-00892-6
PMC
PMC8740500
OpenAlex
W4206281741
Cited by
56
References
9
Citations by year
2026: 5 · 2025: 21 · 2024: 15 · 2023: 11 · 2022: 4
FWCI
1.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Brain (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
Keywords
MEF2C, neuropsychiatric disorders, autism spectrum disorder, epilepsy, schizophrenia, Alzheimer's disease, MADS-box transcription factors, brain development, neuronal differentiation, axon and dendrite development, disease mechanisms
MeSH terms
Autism Spectrum Disorder, Alzheimer Disease, Humans, Neurons, MEF2 Transcription Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review